Re: Pathologic complete responses, long-term outcomes, and recurrence patterns in HER2-low vs. HER2-zero breast cancer after neoadjuvant chemotherapy: Several issues about HER2 expression and neoadjuvant chemotherapy in breast cancer
- PMID: 36581473
- DOI: 10.1016/j.ejca.2022.11.018
Re: Pathologic complete responses, long-term outcomes, and recurrence patterns in HER2-low vs. HER2-zero breast cancer after neoadjuvant chemotherapy: Several issues about HER2 expression and neoadjuvant chemotherapy in breast cancer
Erratum in
-
Corrigendum to "Re: Pathologic complete responses, long-term outcomes, and recurrence patterns in HER2-low vs. HER2-zero breast cancer after neoadjuvant chemotherapy: Several issues about HER2 expression and neoadjuvant chemotherapy in breast cancer" [Eur J Cancer 180 (2023) 184-185].Eur J Cancer. 2024 Mar;200:113559. doi: 10.1016/j.ejca.2024.113559. Epub 2024 Feb 2. Eur J Cancer. 2024. PMID: 38310078 No abstract available.
Conflict of interest statement
Conflict of interest statement The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Comment in
-
Response to letter entitled: Re: Pathologic Complete Responses, Long-term Outcomes, and Recurrence Patterns in HER2-low vs. HER2-zero Breast Cancer after Neoadjuvant Chemotherapy.Eur J Cancer. 2023 Feb;180:186-188. doi: 10.1016/j.ejca.2022.11.019. Epub 2022 Dec 16. Eur J Cancer. 2023. PMID: 36529603 No abstract available.
Comment on
-
Pathological complete response, long-term outcomes, and recurrence patterns in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy.Eur J Cancer. 2022 Nov;176:30-40. doi: 10.1016/j.ejca.2022.08.031. Epub 2022 Sep 29. Eur J Cancer. 2022. PMID: 36183652
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous